Experimental combo for skin cancer shows early promise but study halted

NCT ID NCT03901573

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded to previous treatments or who had not yet tried similar drugs. The study was stopped early, but researchers looked at safety and tumor shrinkage to guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous neuroendocrine carcinoma melanoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44106, United States

  • Dana Farber

    Boston, Massachusetts, 02215, United States

  • MGH

    Boston, Massachusetts, 02215, United States

  • Mt Sinai

    New York, New York, 10029, United States

  • Northwestern University

    Chicago, Illinois, 60208, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Washington University

    St Louis, Missouri, 63110, United States